<DOC>
	<DOCNO>NCT01962987</DOCNO>
	<brief_summary>To compare relative efficacy safety test formulation diclofenac sodium gel 3 % ( Actavis ) market formulation Solaraze® ( diclofenac sodium ) Gel 3 % ( Fougera Pharms ) treatment actinic keratosis</brief_summary>
	<brief_title>A Study Comparing Diclofenac Sodium Gel 3 % Solaraze® ( Diclofenac Sodium ) Gel 3 % Treatment Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>1 . Signed informed consent form , meet criteria current FDA HIPAA regulation . 2 . Immunocompetent male nonpregnant , nonlactating female least 18 year age . 3 . Diagnosis AK ≥ 5 &lt; 10 clinically typical , visible , discrete , nonhyperkeratotic , nonhypertrophic AK lesion least 4 mm diameter face and/or bald scalp contain within 25cm2 treatment area . 4 . Women either must 1 year postmenopausal ( menstrual period least 12 month ) , surgically sterile , childbearing potential , must : 1 . Have use systemic birth control , IUD , Norplant least 28 day prior start treatment period study , use barrier method diaphragm plus spermicide condom plus spermicide consistently , least 14 day study gel administration . 2 . Had normal menstrual cycle month prior start treatment . 3 . Have negative urine pregnancy test result upon entry study . 4 . Agree use medically accept form birth control ( oral , implant , injectable transdermal contraceptive , intrauterine device , condom plus spermicide , diaphragm plus spermicide ) practice abstinence throughout study period . 5 . Free systemic dermatologic disorder , opinion Investigator , interfere study result increase risk AEs . 6 . Any skin type race , provide skin pigmentation allow discernment erythema . 7 . Willingness capability cooperate extent degree require protocol . 1 . Active gastrointestinal ulceration bleeding . 2 . Current history severe renal hepatic impairment . 3 . Presence atopic dermatitis , basal cell carcinoma , squamous cell carcinoma , eczema , psoriasis , rosacea , sunburn possible skin condition face bald scalp investigator 's opinion would interfere study assessment . 4 . Use within six month prior randomization oral isotretinoin . 5 . Use within six month prior randomization face bald scalp 1 ) chemical peel , 2 ) dermabrasion , 3 ) laser abrasion , 4 ) PUVA ( psoralen plus ultraviolet A ) therapy , 5 ) UVB therapy 6 . Use within one month prior randomization face bald scalp 1 ) cryodestruction chemodestruction , 2 ) curettage , 3 ) photodynamic therapy , 4 ) surgical excision , 5 ) topical 5fluorouracil , 6 ) topical corticosteroid , 7 ) topical diclofenac , 8 ) topical Imiquimod , 9 ) topical retinoids , 10 ) treatment actinic keratosis include glycolic acid overthecounter product contain retinol , alpha beta hydroxy acid . 7 . Use within one month prior randomization 1 ) immunomodulators immunosuppressive therapy , 2 ) interferon , 3 ) systemic corticosteroid 4 ) cytotoxic drug . ( The occasional use ophthalmic , nasal inhaled steroid acceptable reason exclusion ) 8 . Known allergy diclofenac sodium , benzyl alcohol , polyethylene glycol monomethyl ether 359 , hyaluronate sodium excipients test reference gel . 9 . Receiving 5Fluorouracil systemic cancer chemotherapy within 6 month prior randomization . 10 . Any condition , medical , psychological , social , , Investigator 's opinion , would interfere participation study . 11 . Women pregnant , plan pregnancy lactate . 12 . Participation investigational drug study within 30 day randomization previous participation study . 13 . Employees research center Investigator . 14 . Family member employee research center Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>